Taysha Gene Therapies Stock (NASDAQ:TSHA)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$2.65

52W Range

$1.05 - $3.31

50D Avg

$2.60

200D Avg

$2.03

Market Cap

$698.29M

Avg Vol (3M)

$3.93M

Beta

0.95

Div Yield

TSHA Company Profile

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Sep 24, 2020

Website

TSHA Performance

TSHA Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$8.33M	$15.45M	$2.50M
Operating Income	$-91.46M	$-72.44M	$-162.45M
Net Income	$-89.30M	$-111.57M	$-169.58M
EBITDA	$-91.46M	$-105.20M	$-159.73M
Basic EPS	$-0.36	$-0.96	$-3.86
Diluted EPS	$-0.36	$-0.96	$-3.86

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 25May 15, 25 | 8:30 AM

Q4 24Feb 26, 25 | 8:30 AM

Q3 24Nov 13, 24 | 4:30 PM

Peer Comparison

Ticker	Company
FHTX	Foghorn Therapeutics Inc.
CCCC	C4 Therapeutics, Inc.
SPRB	Spruce Biosciences, Inc.
FDMT	4D Molecular Therapeutics, Inc.
CABA	Cabaletta Bio, Inc.
PASG	Passage Bio, Inc.
PRLD	Prelude Therapeutics Incorporated
STTK	Shattuck Labs, Inc.